KalVista Pharmaceuticals (KALV) News Today $11.13 +0.13 (+1.18%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$11.12 -0.01 (-0.09%) As of 10/24/2025 05:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock KALV Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period KalVista Pharmaceuticals (NASDAQ:KALV) Earns "Sell (D-)" Rating from Weiss RatingsOctober 10, 2025 | marketbeat.comKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Given Consensus Rating of "Moderate Buy" by BrokeragesOctober 8, 2025 | marketbeat.comKalVista: Prophylaxis Is Shrinking The Acute HAE TAMOctober 7, 2025 | seekingalpha.comKalVista presents new data on Ekterly in EuropeOctober 6, 2025 | msn.comKalVista Pharmaceuticals (NASDAQ:KALV) Stock Price Down 4% - Should You Sell?October 6, 2025 | marketbeat.comKalVista Pharmaceuticals Presents New Data Highlighting the Potential of EKTERLY® (sebetralstat) to Transform On-Demand Hereditary Angioedema Treatment in EuropeOctober 6, 2025 | businesswire.comKalVista Pharmaceuticals Announces Appointment of Bethany L. Sensenig to Board of DirectorsOctober 2, 2025 | businesswire.comKalVista Pharmaceuticals (NASDAQ:KALV) Shares Pass Below 50-Day Moving Average - Time to Sell?October 1, 2025 | marketbeat.comKalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the 20th German Allergy CongressSeptember 26, 2025 | finance.yahoo.comKalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the 20th German Allergy CongressSeptember 26, 2025 | businesswire.comKalvista Pharmaceuticals stock falls after convertible notes offeringSeptember 25, 2025 | za.investing.comKalVista announces $110M convertible senior notes offeringSeptember 25, 2025 | msn.comKalVista Pharmaceuticals Shares Drop After Notes Offering PricesSeptember 25, 2025 | marketwatch.comKalVista Pharmaceuticals (NASDAQ:KALV) Shares Down 6.9% - What's Next?September 25, 2025 | marketbeat.comKalVista Prices Upsized Offering of $125.0 Million of 3.250% Convertible Senior Notes Due 2031September 24, 2025 | businesswire.comKalVista Pharmaceuticals Announces Proposed Offering of $110.0 Million of Convertible Senior NotesSeptember 24, 2025 | businesswire.comStocks To Watch: KalVista Pharmaceuticals Sees Relative Strength Rating Jump To 83September 19, 2025 | msn.comKalVista Pharmaceuticals’ Hereditary Angioedema Drug Approved In EU, Switzerland: Retail Sees Stock Rallying To $22 In A YearSeptember 19, 2025 | msn.comKalVista Pharmaceuticals Announces European Commission and Swissmedic Approval of EKTERLY® (sebetralstat), First and Only Oral On-Demand Treatment for Hereditary AngioedemaSeptember 19, 2025 | businesswire.comKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives Average Recommendation of "Buy" from AnalystsSeptember 15, 2025 | marketbeat.comKalVista Pharmaceuticals (NASDAQ:KALV) Stock Price Down 4.4% After Earnings MissSeptember 14, 2025 | marketbeat.comNeedham & Company LLC Reiterates Buy Rating for KalVista Pharmaceuticals (NASDAQ:KALV)September 14, 2025 | marketbeat.comKalVista Pharmaceuticals (NASDAQ:KALV) Price Target Raised to $28.00September 14, 2025 | marketbeat.comKalVista Pharmaceuticals (NASDAQ:KALV) Shares Gap Up - Time to Buy?September 13, 2025 | marketbeat.comKalVista Pharmaceuticals (NASDAQ:KALV) Announces Earnings ResultsSeptember 13, 2025 | marketbeat.comKalVista Pharmaceuticals, Inc. $KALV Shares Bought by Woodline Partners LPSeptember 13, 2025 | marketbeat.comKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Q1 2026 Earnings Call TranscriptSeptember 12, 2025 | insidermonkey.comKalVista Pharmaceuticals Inc (KALV) Q1 2026 Earnings Call Highlights: EKTERLY Launch Drives ...September 12, 2025 | finance.yahoo.comKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Q1 2026 Earnings Call TranscriptSeptember 12, 2025 | msn.comBenjamin Palleiko Sells 7,294 Shares of KalVista Pharmaceuticals (NASDAQ:KALV) StockSeptember 11, 2025 | marketbeat.comKalVista Pharmaceuticals’ Earnings Call Highlights EKTERLY SuccessSeptember 11, 2025 | tipranks.comKalVista Pharmaceuticals, Inc. (KALV) Q1 2026 Earnings Call TranscriptSeptember 11, 2025 | seekingalpha.comKalVista Pharmaceuticals, Inc. 2026 Q1 - Results - Earnings Call PresentationSeptember 11, 2025 | seekingalpha.comEarnings Scheduled For September 11, 2025September 11, 2025 | benzinga.comKalVista Pharmaceuticals Provides Operational Update and Reports Fiscal Quarter Financial ResultsSeptember 11, 2025 | finance.yahoo.comKalVista Pharmaceuticals (NASDAQ:KALV) Hits New 52-Week High - Here's What HappenedSeptember 10, 2025 | marketbeat.comInsider Selling: KalVista Pharmaceuticals (NASDAQ:KALV) CEO Sells 7,294 Shares of StockSeptember 10, 2025 | insidertrades.comAdage Capital Partners GP L.L.C. Sells 24,000 Shares of KalVista Pharmaceuticals, Inc. $KALVSeptember 9, 2025 | marketbeat.comParkman Healthcare Partners LLC Takes $8.70 Million Position in KalVista Pharmaceuticals, Inc. $KALVSeptember 8, 2025 | marketbeat.comInvesco Ltd. Boosts Stake in KalVista Pharmaceuticals, Inc. $KALVSeptember 8, 2025 | marketbeat.comKalVista Pharmaceuticals, Inc. (KALV) Presents At Cantor Global Healthcare Conference 2025 TranscriptSeptember 7, 2025 | seekingalpha.comNuveen LLC Takes Position in KalVista Pharmaceuticals, Inc. $KALVSeptember 7, 2025 | marketbeat.comRafferty Asset Management LLC Has $303,000 Stake in KalVista Pharmaceuticals, Inc. $KALVSeptember 6, 2025 | marketbeat.comKalVista Pharmaceuticals, Inc. $KALV Stock Holdings Lessened by Allostery Investments LPSeptember 5, 2025 | marketbeat.comKalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 4, 2025 | finanznachrichten.deKalVista Pharmaceuticals (NASDAQ:KALV) Stock Price Up 5.8% - Here's WhySeptember 4, 2025 | marketbeat.comVestal Point Capital LP Has $54.83 Million Position in KalVista Pharmaceuticals, Inc. $KALVSeptember 4, 2025 | marketbeat.comKalVista Pharmaceuticals to Provide Operational Update and Fiscal Quarter Financial Results on September 11, 2025September 4, 2025 | businesswire.comKalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 4, 2025 | businesswire.comDAFNA Capital Management LLC Sells 59,319 Shares of KalVista Pharmaceuticals, Inc. $KALVSeptember 1, 2025 | marketbeat.com Get KalVista Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for KALV and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. KALV Media Mentions By Week KALV Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. KALV News Sentiment▼0.830.84▲Average Medical News Sentiment KALV News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. KALV Articles This Week▼25▲KALV Articles Average Week Get the Latest News and Ratings for KALV and Related Stocks Enter your email address to receive the latest news and analysts' ratings for KalVista Pharmaceuticals and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies SRPT News ETNB News MESO News OCUL News ANIP News VERA News COGT News STOK News VCEL News RCUS News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:KALV) was last updated on 10/26/2025 by MarketBeat.com Staff From Our PartnersU.S. Government Sparking Crypto RallyMissed Bitcoin when it was $100? You’re not alone. Crypto runs in cycles—and the next one is already underw...Crypto 101 Media | SponsoredIt’s Time to Buy “the NVIDIA of Quantum Computing”Yahoo Finance wrote that investing in quantum computing could... "Lead to life-changing returns... and make...Brownstone Research | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredBuy the dip? Here’s my #1 gold stock“The most obvious opportunity in gold stocks I’ve seen in my career” While everyone is distracted by gold’s...Golden Portfolio | SponsoredThe strategy that wins no matter where the market goesJoel and Adam have built a crypto trading system with a 93% win rate — even through volatile, sideways markets...Crypto Swap Profits | SponsoredOptions Pro Reveals His #1 Retirement Income TradeIf you want a way to generate consistent market income without chasing volatile AI stocks or complex crypto tr...Base Camp Trading | SponsoredElon Musk is on the lineElon Musk says November 6 could "affect the future of the world" Get ready for the biggest pivot in corpora...Altimetry | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding KalVista Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share KalVista Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
